<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Garratt, Kirk</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TL-PAS Shows Reduction of Ischemic Events with Long-Term Prasugrel</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">The results of the multicenter TAXUS Liberté Post Approval Study [TL-PAS] are discussed in this article. Patients randomized in this prospective open-label study were also participants in the Dual Antiplatelet Therapy Study. While the TL-PAS was not powered to show a difference in the end point analyses, the results from this specific trial were presented.</style></abstract><number><style face="normal" font="default" size="100%">52</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>